company background image
S5YA

Sigma Healthcare DB:S5YA Stock Report

Last Price

AU$0.32

Market Cap

AU$329.6m

7D

11.2%

1Y

-21.3%

Updated

19 May, 2022

Data

Company Financials +
S5YA fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance0/6
Financial Health3/6
Dividends1/6

S5YA Stock Overview

Sigma Healthcare Limited, together with its subsidiaries, engages in the wholesale and distribution of pharmaceutical products primarily in Australia.

Sigma Healthcare Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sigma Healthcare
Historical stock prices
Current Share PriceAU$0.32
52 Week HighAU$0.41
52 Week LowAU$0.26
Beta-0.024
1 Month Change-0.63%
3 Month Change11.97%
1 Year Change-21.29%
3 Year Change0.95%
5 Year Change-36.65%
Change since IPO-49.52%

Recent News & Updates

Shareholder Returns

S5YADE HealthcareDE Market
7D11.2%-1.1%0.7%
1Y-21.3%-22.2%-13.3%

Return vs Industry: S5YA underperformed the German Healthcare industry which returned -19% over the past year.

Return vs Market: S5YA underperformed the German Market which returned -11.1% over the past year.

Price Volatility

Is S5YA's price volatile compared to industry and market?
S5YA volatility
S5YA Average Weekly Movement6.2%
Healthcare Industry Average Movement5.1%
Market Average Movement6.4%
10% most volatile stocks in DE Market10.8%
10% least volatile stocks in DE Market3.5%

Stable Share Price: S5YA is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: S5YA's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1912n/aVikesh Ramsunderhttps://www.sigmahealthcare.com.au

Sigma Healthcare Limited, together with its subsidiaries, engages in the wholesale and distribution of pharmaceutical products primarily in Australia. It operates approximately 1,200 branded and independent pharmacy stores under the Amcal, Discount Drug Stores, Guardian, WholeLife, and PharmaSave brands. The company also provides hospital pharmacy wholesale services; dose administration aid services to the aged care sector, community pharmacy sector, and in the home; technology solutions and data analytics; and product development and support for a range of private and exclusive label products, as well as supplies medical consumables and devices to a broad range of customers, including pharmacy aged care facilities, hospitals, and clinics.

Sigma Healthcare Fundamentals Summary

How do Sigma Healthcare's earnings and revenue compare to its market cap?
S5YA fundamental statistics
Market CapAU$494.37m
Earnings (TTM)-AU$7.24m
Revenue (TTM)AU$3.45b

0.1x

P/S Ratio

-68.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
S5YA income statement (TTM)
RevenueAU$3.45b
Cost of RevenueAU$3.22b
Gross ProfitAU$227.11m
Other ExpensesAU$234.35m
Earnings-AU$7.24m

Last Reported Earnings

Jan 31, 2022

Next Earnings Date

Sep 22, 2022

Earnings per share (EPS)-0.0073
Gross Margin6.59%
Net Profit Margin-0.21%
Debt/Equity Ratio36.9%

How did S5YA perform over the long term?

See historical performance and comparison

Dividends

4.0%

Current Dividend Yield

-273%

Payout Ratio

Valuation

Is Sigma Healthcare undervalued compared to its fair value and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: S5YA (€0.32) is trading below our estimate of fair value (€1.41)

Significantly Below Fair Value: S5YA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: S5YA is unprofitable, so we can't compare its PE Ratio to the German Healthcare industry average.

PE vs Market: S5YA is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate S5YA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: S5YA is good value based on its PB Ratio (1x) compared to the DE Healthcare industry average (1.3x).


Future Growth

How is Sigma Healthcare forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

Future Growth Score

3/6

Future Growth Score 3/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


64.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: S5YA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.05%).

Earnings vs Market: S5YA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: S5YA's is expected to become profitable in the next 3 years.

Revenue vs Market: S5YA's revenue (3.2% per year) is forecast to grow slower than the German market (4.9% per year).

High Growth Revenue: S5YA's revenue (3.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: S5YA's Return on Equity is forecast to be low in 3 years time (6.5%).


Past Performance

How has Sigma Healthcare performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-23.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: S5YA is currently unprofitable.

Growing Profit Margin: S5YA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: S5YA is unprofitable, and losses have increased over the past 5 years at a rate of 23.3% per year.

Accelerating Growth: Unable to compare S5YA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: S5YA is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (55.1%).


Return on Equity

High ROE: S5YA has a negative Return on Equity (-1.3%), as it is currently unprofitable.


Financial Health

How is Sigma Healthcare's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: S5YA's short term assets (A$761.6M) exceed its short term liabilities (A$457.6M).

Long Term Liabilities: S5YA's short term assets (A$761.6M) exceed its long term liabilities (A$301.9M).


Debt to Equity History and Analysis

Debt Level: S5YA's net debt to equity ratio (30.5%) is considered satisfactory.

Reducing Debt: S5YA's debt to equity ratio has increased from 6.3% to 36.9% over the past 5 years.

Debt Coverage: S5YA's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: S5YA's interest payments on its debt are not well covered by EBIT (0.4x coverage).


Balance Sheet


Dividend

What is Sigma Healthcare current dividend yield, its reliability and sustainability?

Dividend Score

2/6

Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


4.00%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: S5YA's dividend (4%) is higher than the bottom 25% of dividend payers in the German market (1.39%).

High Dividend: S5YA's dividend (4%) is low compared to the top 25% of dividend payers in the German market (4.41%).


Stability and Growth of Payments

Stable Dividend: S5YA's dividend payments have been volatile in the past 10 years.

Growing Dividend: S5YA's dividend payments have fallen over the past 10 years.


Earnings Payout to Shareholders

Earnings Coverage: S5YA is paying a dividend but the company is unprofitable.


Cash Payout to Shareholders

Cash Flow Coverage: S5YA is paying a dividend but the company has no free cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

0.3yrs

Average management tenure


CEO

Vikesh Ramsunder (50 yo)

0.25

Tenure

Mr. Vikesh Ramsunder, B.Com, MBL, has been Chief Executive Officer and Managing Director of Sigma Healthcare Limited since February 01, 2022 and serves as its Director since February 17, 2022. He served as...


Leadership Team

Experienced Management: S5YA's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: S5YA's board of directors are considered experienced (6.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: S5YA insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Sigma Healthcare Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Sigma Healthcare Limited
  • Ticker: S5YA
  • Exchange: DB
  • Founded: 1912
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Implied Market Cap: AU$494.370m
  • Listing Market Cap: AU$329.591m
  • Shares outstanding: 988.74m
  • Website: https://www.sigmahealthcare.com.au

Location

  • Sigma Healthcare Limited
  • 3 Myer Place
  • Rowville
  • Victoria
  • 3178
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/19 00:00
End of Day Share Price2022/05/19 00:00
Earnings2022/01/31
Annual Earnings2022/01/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.